Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018 Year: 2019
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012
Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysisSource: Eur Respir J, 50 (4) 1701044; 10.1183/13993003.01044-2017 Year: 2017
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1600803; DOI: 10.1183/13993003.00803-2016 Year: 2017
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1526-1527 Year: 2016
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1527-1529 Year: 2016
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis Source: Eur Respir J, 55 (1) 1901181; 10.1183/13993003.01181-2019 Year: 2020
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019
The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline Source: Eur Respir J 2016; 48: 935-938 Year: 2016
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018 Year: 2018
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence Source: Eur Respir J 2016; 47: 394-402 Year: 2016
Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials Source: Eur Respir Rev 2015; 25: 29-35 Year: 2016